Identification of prognostic and bone metastasis​‐related alternative splicing signatures in mesothelioma

Bibliographic Details
Title: Identification of prognostic and bone metastasis​‐related alternative splicing signatures in mesothelioma
Authors: Runzhi Huang, Zixuan Zheng, Sijia Liu, Penghui Yan, Dianwen Song, Huabin Yin, Peng Hu, Xiaolong Zhu, Zhengyan Chang, Yihan Liu, Juanwei Zhuang, Tong Meng, Zongqiang Huang, Jie Zhang
Source: Cancer Medicine, Vol 10, Iss 13, Pp 4478-4492 (2021)
Publisher Information: Wiley, 2021.
Publication Year: 2021
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: alternative splicing, mesothelioma, metastasis, prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Mesothelioma (MESO) is an infrequent tumor derived from mesothelial cells of pleura, peritoneum, pericardium, and tunica vaginalis testis. Despite advancement in technologies and better understanding of tumor progression mechanism, the prognosis of MESO remains poor. The role of alternative splicing events (ASEs) in the oncogenesis, tumor metastasis and drug resistance has been widely discussed in multiple cancers. But the prognosis and potential therapeutic value of ASEs in MESO were not clearly studied by now. We constructed a prognostic model using RNA sequencing data and matched ASE data of MESO patients obtained from the TCGA and TCGASpliceSeq database. A total of 3,993 ASEs were identified associated with overall survival using Cox regression analysis. Eight of them were finally figured out to institute the model by lasso regression analysis. The risk score of the model can predict the prognosis independently. Among the identified 390 splicing factors (SF), HSPA1A and DDX3Y was significantly associated with 43 OS‐SEs. Among these OS‐SEs, SNX5‐58744‐AT (p = 0.048) and SNX5‐58745‐AT (p = 0.048) were significantly associated with bone metastasis. Co‐expression analysis of signal pathways and SNX5‐58744‐AT, SNX5‐58745‐AT was also depicted using GSVA. Finally, we proposed that splicing factor (SF) HSPA1A could regulate SNX5‐58744‐AT (R = −0.414) and SNX5‐58745‐AT (R = 0.414) through the pathway “Class I MHC mediated antigen processing and presentation” (R = 0.400). In this way, tumorigenesis and bone metastasis of MESO were controlled.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2045-7634
Relation: https://doaj.org/toc/2045-7634
DOI: 10.1002/cam4.3977
Access URL: https://doaj.org/article/598d8be05655400d9ef4164a142d85e8
Accession Number: edsdoj.598d8be05655400d9ef4164a142d85e8
Database: Directory of Open Access Journals
More Details
ISSN:20457634
DOI:10.1002/cam4.3977
Published in:Cancer Medicine
Language:English